Daewoong Pharmaceutical acquires sale right and license of Sandoz’s osteoporosis treatment

Published: 2017-10-13 16:26:00
Updated: 2017-10-13 15:39:33

Daewoong Pharmaceutical(CEO Jong-Wook Lee) announce the company acquired a Korean sale right and license of ‘Zoledronic Acid Inj 5mg/100ml,’ a osteoporosis treatment, from Novartis and Sandoz Korea.

Under the distribution/promotion agreement with Sandoz Korea, Daewoong Pharmaceutical has exclusi...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.